Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis

International Journal of Dermatology

Volumn 40, Issue 3, 2001, Pages 210-212

  Koo, John Y M ^a,b   Martin, Dale ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; STEROID; TAZAROTENE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DERMATITIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT SATISFACTION; PRURITUS; PSORIASIS; SCORING SYSTEM; SELF REPORT; STATISTICAL ANALYSIS; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; OINTMENTS; PREGNADIENEDIOLS; PRURITUS; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 0034955338     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2001.01167.x     Document Type: Article

References (3)

1. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis
2. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy
3. Tazarotene 0.1% gel, with and without a high potency or mid-high potency corticosteroid, in the treatment of stable plaque psoriasis